On Monday, GC Medical Science announced that it had signed a memorandum of understanding (MOU) to establish a strategic partnership with Jiangsu Yuwell Medical Equipment Co., Ltd. at the Chinese company’s headquarters.
This agreement aims to expand GC Medical Science’s existing collaboration with Yuwell in home healthcare products through its GCFiT brand into the Continuous Glucose Monitoring (CGM) sector. The partnership also seeks to strengthen the company’s blood glucose management product portfolio and competitiveness in the domestic market.
GCFiT, which stands for medical devices that fit (i) my health, is GC Medical Science’s home medical device brand. Since last year, the company has been expanding into the business-to-consumer (B2C) home medical device market, introducing the personal GCFiT blood glucose meter.
CGM is a medical device that continuously measures glucose levels through a skin-attached sensor, allowing users to monitor blood sugar changes over time. GC Medical Science plans to enhance its blood glucose management product line by integrating CGM with its existing self-monitoring blood glucose meters.
The two companies will collaborate on regulatory tasks for the domestic introduction of Yuwell’s CGM products. This includes securing technical documents and clinical data, as well as preparing for domestic testing and certification. GC Medical Science will handle domestic regulatory compliance, marketing, sales, and distribution, while Yuwell will provide technical and regulatory documents for product manufacturing and quality assurance.
Specific business conditions, such as product pricing, purchase volumes, exclusivity terms, data security, and localization, will be finalized through future negotiations.
Through this collaboration, GC Medical Science aims to expand its blood glucose management product portfolio. By combining Yuwell’s product development and manufacturing capabilities with its own domestic regulatory, sales, and distribution strengths, the company seeks to enhance its competitiveness in the home healthcare market.
A GC Medical Science representative stated that this agreement is a stepping stone to expand the existing GCFiT product line, which focuses on blood glucose meters, into the CGM sector. It will work closely with Yuwell to promote domestic regulatory approval and market entry, continuously expanding the blood glucose management product line to meet various consumer needs.
Yuwell, established in 1998 in Danyang, Jiangsu Province, is a publicly listed medical device company on the Shenzhen Stock Exchange. It develops and manufactures a variety of home medical devices, including blood pressure monitors, blood glucose meters, oxygen generators, and nebulizers, as well as products for respiratory management, diabetes care, and rehabilitation.
With a wide range of products from hospital medical devices to home health management products, Yuwell is the leading company in China’s home healthcare market. Its projected revenue for 2025 is approximately 7.955 billion CNY (about 1.18 billion USD).
